Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis

INTRODUCTION: PTK/ZK is a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor receptor, colony-stimulating factor 1 receptor, and cytokine stem cell factor receptor. Cetuximab is a monoclonal antibody against epidermal growth fact...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Langenberg, Marlies HG, Witteveen, Petronella O, Lankheet, Nienke AG, Roodhart, Jeanine ML, Rosing, Hilde, van den Heuvel, Ingeborg JGM, Beijnen, Jos H, Voest, Emile E
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Neoplasia Press Inc. 2010
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2814358/
https://ncbi.nlm.nih.gov/pubmed/20126478
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items